Bipolar II Disorder Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Bipolar II Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Bipolar I DisorderBipolar II Disorder
AbbVie195 enrolled22 locationsNCT06696755
Recruiting

LHC-CIDI-5 in Hong Kong

Suicidal IdeationObsessive Compulsive Disorder (OCD)Major Depressive Disorder (MDD)+20 more
The University of Hong Kong2,500 enrolled1 locationNCT06804525
Recruiting
Phase 4

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

ObesityWeight LossBipolar I Disorder+3 more
Mayo Clinic100 enrolled1 locationNCT07213466
Recruiting
Phase 3

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Bipolar DisorderBipolar I DisorderBipolar II Disorder+1 more
Xenon Pharmaceuticals Inc.400 enrolled26 locationsNCT07172516
Recruiting
Not Applicable

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

Bipolar II DisorderBipolar II Disorder, Most Recent Episode Major Depressive
Andrew Krystal10 enrolled1 locationNCT07127913
Recruiting
Phase 2

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Bipolar II DisorderDepression BipolarSuicidality
The University of Texas Health Science Center, Houston10 enrolled1 locationNCT06706232
Recruiting
Phase 2

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

Cannabis UseBipolar DisorderSchizoaffective Disorder, Bipolar Type+5 more
Medical University of South Carolina68 enrolled1 locationNCT05064319
Recruiting
Not Applicable

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

Treatment Resistant DepressionBipolar II Disorder, Most Recent Episode Major DepressiveCurrent Depressive Episode
Stanford University60 enrolled1 locationNCT05849402